Project Grant HT94252310006
Award Date
4/1/23
Completion Date
3/31/25
Dollars Obligated
$160K
Federal Agency
Defense Health Agency
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
The Defense Health Agency awarded Emory University a $160,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of April 1, 2023 through March 31, 2025. The grant will support GENOME-WIDE ANALYSES OF PROTEIN-DNA INTERACTION USING LONG-READ SEQUENCING. Through this funding, Emory University will conduct research using long-read sequencing to analyze protein-DNA interactions on a genome-wide scale. The Military Medical Research and Development...
The Defense Health Agency awarded Emory University a $156,500 project grant under the Military Medical Research and Development program to support research on core transcription factors in regenerative medicine and cancer. The one-year award beginning September 30, 2023 will fund investigation into medical solutions for the battlefield by transforming healthcare through innovative biomedical research. Specifically, Emory University will conduct research on core transcription factors as they...
The Defense Health Agency awarded Emory University a $305,175 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on a novel therapeutic target for renal medullary carcinoma. The award period runs from July 1, 2023 to June 30, 2026. As a leading research university, Emory has a strong track record of delivering scientific research and public health services under federal grants and contracts. This award supports Emory's expertise in...
Emory University will conduct research under a $1,255,611 Project Grant from the Defense Health Agency through the Military Medical Research and Development program. The three-year award beginning in April 2023 will fund research to define the molecular basis for immunogenicity of locally advanced prostate tumors resistant to androgen deprivation therapy. The CFDA 12.420 program supports basic, applied and advanced biomedical research to transform military and public health care through...
Emory University was awarded a $586,875 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2026 to elucidate and exploit SAMHD1 for breast cancer therapy. Through this funding, Emory University researchers will investigate medical solutions for breast cancer by exploring the role of the SAMHD1 protein and developing new therapeutic approaches for...
Emory University was awarded a $586,875 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2026 to elucidate and exploit SAMHD1 for breast cancer therapy. Through this funding, Emory University researchers will investigate medical solutions for breast cancer by exploring the role of the SAMHD1 protein and developing new therapeutic approaches for...
This Project Grant, awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), provides $625,994 to Emory University to support research on novel cell therapy approaches for neuroblastoma. The project aims to advance the development of new treatments for this type of pediatric cancer, which is a priority area for military medical research. Emory University, a leading academic research institution, is well-positioned to conduct this work,...
This federal Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) provides $568,687 to Emory University to develop novel radiogenomic tools for predicting outcomes for small cell lung cancer patients treated with chemoimmunotherapy. The project, with a performance period from February 1, 2024 to January 31, 2027, aims to advance scientific knowledge and improve clinical outcomes in this patient population through...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $187,800.00 to Emory University to conduct research on "ENHANCING RADIOSENSITIVITY IN CHD5-DEPLETED LUNG ADENOCARCINOMA THROUGH INHIBITION OF NONHOMOLOGOUS END JOINING (NHEJ)." The award, which runs from March 15, 2025 to March 14, 2026, aims to explore innovative approaches to improve the effectiveness of radiation therapy for lung cancer...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,331,869.00 to Emory University to conduct research on "Therapeutic Targeting of Aurora Kinase A in Lethal Prostate Cancer Using a Novel Inhibitor". The three-year project aims to investigate medical solutions for the battlefield through innovative biomedical research. Emory University is the prime awardee, and they have subcontracted a portion of...